Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique.
The aim of this pilot study was to evaluate whether the technique of magnetic fluid hyperthermia can be used for minimally invasive treatment of prostate cancer. This paper presents the first clinical application of interstitial hyperthermia using magnetic nanoparticles in locally recurrent prostate cancer. Treatment planning was carried out using computerized tomography (CT) of the prostate. Based on the individual anatomy of the prostate and the estimated specific absorption rate (SAR) of magnetic fluids in prostatic tissue, the number and position of magnetic fluid depots required for sufficient heat deposition was calculated while rectum and urethra were spared. Nanoparticle suspensions were injected transperineally into the prostate under transrectal ultrasound and flouroscopy guidance. Treatments were delivered in the first magnetic field applicator for use in humans, using an alternating current magnetic field with a frequency of 100 kHz and variable field strength (0-18 kA m(-1)). Invasive thermometry of the prostate was carried out in the first and last of six weekly hyperthermia sessions of 60 min duration. CT-scans of the prostate were repeated following the first and last hyperthermia treatment to document magnetic nanoparticle distribution and the position of the thermometry probes in the prostate. Nanoparticles were retained in the prostate during the treatment interval of 6 weeks. Using appropriate software (AMIRA), a non-invasive estimation of temperature values in the prostate, based on intra-tumoural distribution of magnetic nanoparticles, can be performed and correlated with invasively measured intra-prostatic temperatures. Using a specially designed cooling device, treatment was well tolerated without anaesthesia. In the first patient treated, maximum and minimum intra-prostatic temperatures measured at a field strength of 4.0-5.0 kA m(-1) were 48.5 degrees C and 40.0 degrees C during the 1st treatment and 42.5 degrees C and 39.4 degrees C during the 6th treatment, respectively. These first clinical experiences prompted us to initiate a phase I study to evaluate feasibility, toxicity and quality of life during hyperthermia using magnetic nanoparticles in patients with biopsy-proven local recurrence of prostate cancer following radiotherapy with curative intent. To the authors' knowledge, this is the first report on clinical application of interstitial hyperthermia using magnetic nanoparticles in the treatment of human cancer.
Johannsen
M
M
Department of Urology, Charité--Campus Mitte, Schumannstr. 20/21, 10117 Berlin, Germany. manfred.johannsen@charite.de
Gneveckow
U
U
Eckelt
L
L
Feussner
A
A
Waldöfner
N
N
Scholz
R
R
Deger
S
S
Wust
P
P
Loening
S A
SA
Jordan
A
A
D000368:Aged; D003131:Combined Modality Therapy; D005290:Ferric Compounds / Q000627:therapeutic use; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D008280:Magnetics / Q000627:therapeutic use*; D008297:Male; D049329:Nanostructures; D010347:Patient Care Planning; D010865:Pilot Projects; D011471:Prostatic Neoplasms / Q000628:therapy*
D005290:Ferric Compounds; C000499:ferric oxide